Naproxen etemesil is a lipophilic, non-acidic, inactive prodrug of the non-steroidal anti-inflammatory drug (NSAID) naproxen that is hydrolysed to pharmacologically active naproxen once absorbed. Naproxen etemesil was in development with Logical Therapeutics for the treatment of osteoarthritis. However, no recent development has been reported. It is also in phase I clinical trials for the treatment of inflammation and arthritis.The compound was originally developed by Medinox, licensed to Logical Therapeutics in 2006 for partial rights.

Phetharbital (Pyrictal), a barbiturate with virtually no hypnotic side effects, was originally introduced for the management of epilepsy and has since been shown to have powerful hepatic enzyme-inducing properties. In preliminary clinical studies, phetharbital was found to be effective against febrile seizures, minor myoclonic seizures and in petit mal. Phetharbital is relatively ineffective in the control of the tonic extensor seizure pattern and would not be expected to modify grand mal tonic seizures. Chronic administration of phetharbital causes an increased excretion of 6 beta-hydroxycortisol in human urine. This increase in 6 beta-hydroxycortisol excretion is not accompanied by an increase in the 17-hydroxycorticosteroids levels in urine, indicating that an increased adrenal output of cortisol is not responsible for the increased urinary levels of 6 beta hydroxycortisol. Phetharbital was also effective in the rare severe unconjugated hyperbilirubinemia of the Crigler-Najjar syndrome.

Vincofos is a broad-spectrum canine anthelmintic. All or nearly all of the ascarids, hookworms, whipworms, and the tapeworm, Taenia pisiformis, were expelled following therapy with vincofos. The tapeworm, Dipylidium caninum, was also effectively removed by the vincofos treatment, but it appeared that a slightly greater dosage would be required to obtain maximum anthelmintic effect.

Temperocol is an investigative anti-cancer drug that inhibits the expression of survivin and CDK-1; discovered at Johns Hopkins University and under development by Erimos Pharmaceuticals. It has been tested in phase I/II clinical trials for Leukemia, and several forms of neoplasms including gliomas. Results of these clinical trials have shown promise, however treatment regimes produce several toxic side effects that need to be balanced against efficacy. Temperocol is a fully methylated derivative of the natural product Nordihydroguaiaretic acid.

Picotrin is the keratolytic agent. It was used for the treatment of acne.

Avoralstat, a small molecule inhibitor of plasma kallikrein, participated in clinical trials phase III to prevent hereditary angioedema, but these studied were discontinued due to insufficient efficacy study. Recently published article has described that avoralstat could improve the quality of life in C1‐INH‐HAE patients. Hereditary angioedema (HAE) with C1 inhibitor deficiency (C1‐INH‐HAE) is an autosomal dominant disorder characterized by recurrent episodes of swelling of the skin, pharynx, gastrointestinal tract, genitals, and is due primarily to mutations in the SERPING1 gene that results in insufficient production of the natural plasma kallikrein inhibitor, C1 inhibitor (C1‐INH).

IPROFENIN is an iminodiacetic acid derivative. Its 99mTc radiolabelled form was used in cholescintigraphy and hepatobiliary scintigraphy to diagnose problems of the liver, gallbladder and bile ducts.

Lesogaberan is a peripherally restricted high-affinity GABAB-R-specific agonist, originally developed for the treatment of gastroesophageal reflux disease (GERD) that appears to be safe for human use. The toxicity profile shows no indication of hepatic effect. Lesogaberan has been shown to induce decreased body weight and decreased food consumption. A dose-dependent diuretic effect was also noted in rats. Treatment with lesogaberan significantly enhanced replication of human islet cells in vitro, which was abrogated by a GABAB-R antagonist. Lesogaberan may be a promising drug candidate for clinical studies of diabetes intervention and islet transplantation. Disappointingly, in phase IIb study it was shown that lesogaberan is only marginally superior to placebo in gastroesophageal reflux disease (GERD) patients who are partially responsive to proton pump inhibitor (PPI) therapy.